111 results match your criteria Clinical Advances in Hematology & Oncology[Journal]


NCI Clinical Trials Planning Meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy.

J Natl Cancer Inst 2019 Jan 31. Epub 2019 Jan 31.

University of Rochester Medical Center, Cancer Control Program, Department of Surgery, Wilmot Cancer Institute, Rochester, NY, USA.

Although recent scientific advances have improved our understanding of basic biological mechanisms underlying chemotherapy-induced peripheral neuropathy (CIPN), few interventions are available to prevent or treat CIPN. While some biological targets from preclinical studies show promise in non-human animal models, few targets have been translated to successful clinical trials. To address this problem, the National Cancer Institute's (NCI's) Symptom Management and Health-Related Quality of Life Steering Committee convened a meeting of experts in the CIPN and oncology symptom management fields to participate in a Clinical Trials Planning Meeting (CTPM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz011DOI Listing
January 2019
1 Read

Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia.

Adv Hematol 2019 1;2019:1835091. Epub 2019 Jan 1.

Department of Biostatistics & Health Informatics, Sanjay Gandhi Post Graduate of Medical Sciences, Raebareli Road, Lucknow, U.P. 226014, India.

Background And Objectives: Chronic myeloid leukemia (CML) is characterized by hyperproliferation of myeloid precursors, increased fibrosis, and neoangiogenesis in the bone marrow. Imatinib inhibits BCR-ABL tyrosine kinase produced due to reciprocal translocation t(9;22) in neoplastic CML cells. It reduces hyperproliferation of myeloid precursors and has been found to affect bone marrow fibrosis and angiogenesis. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ah/2019/1835091/
Publisher Site
http://dx.doi.org/10.1155/2019/1835091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332991PMC
January 2019
4 Reads

Burden of Sickle Cell Disease in Ghana: The Korle-Bu Experience.

Adv Hematol 2018 2;2018:6161270. Epub 2018 Dec 2.

Ghana Institute of Clinical Genetics, Korle-Bu, Accra, Ghana.

In Africa, sickle cell disease (SCD) is a major public health problem with over 200,000 babies born per year. In Ghana, approximately 15,000 (2%) of Ghanaian newborns are diagnosed with SCD annually. A retrospective review of medical records of all SCD patients aged 13 years and above, who presented to the sickle cell clinic at Ghana Institute of Clinical Genetics (GICG), Korle-Bu, from 1st January 2013 to 31st December 2014, was carried out, using a data abstraction instrument to document their phenotypes, demographics, attendance/clinic visits, pattern of attendance, and common complications seen. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ah/2018/6161270/
Publisher Site
http://dx.doi.org/10.1155/2018/6161270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304501PMC
December 2018
11 Reads

Emerging Prognostic Biomarkers in Testicular Germ Cell Tumors: Looking Beyond Established Practice.

Front Oncol 2018 28;8:571. Epub 2018 Nov 28.

Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.

Testicular germ cell tumors are unique among solid cancers. Historically, this disease was deadly if progressed beyond the stage I. The implementation of cisplatin-based chemotherapy regimens has drastically changed the clinical outcome of metastatic testicular cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280583PMC
November 2018
3 Reads

Regulatory T Cells and Profile of FOXP3 Isoforms Expression in Peripheral Blood of Patients with Myelodysplastic Syndromes.

Adv Hematol 2018 10;2018:8487403. Epub 2018 Oct 10.

Celgene International Holdings Corporation, 125047 Moscow, Russia.

We have investigated the frequencies of regulatory T cells and the level of FOXP3 isoforms expression in peripheral blood of patients with myelodysplastic syndromes and found the significant reduction of regulatory T cells at all stages of the disease. At the same time in untreated patients, we observed the shift in the FOXP3 isoforms expression profile towards the full-length molecule possibly due to inflammation. Based on the already known information about the potentially higher functional activity of FOXP3 molecule lacking exon 2, we have also hypothesized that our finding may explain the high risk of autoimmune disorders in this disease. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ah/2018/8487403/
Publisher Site
http://dx.doi.org/10.1155/2018/8487403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199869PMC
October 2018
6 Reads

Vitamin D and Nonskeletal Complications among Egyptian Sickle Cell Disease Patients.

Adv Hematol 2018 16;2018:3867283. Epub 2018 Sep 16.

Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.

Lower levels of vitamin D have been documented in many patients with sickle cell disease (SCD), but data are still inconclusive regarding the association between vitamin D deficiency (VDD) and the occurrence or the severity of various SCD complications. Our study aimed to detect the prevalence of vitamin D deficiency among Egyptian patients with SCD and to associate it with the clinical course of the disease. We measured the level of 25-hydroxy vitamin D in 140 children (age from 4. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ah/2018/3867283/
Publisher Site
http://dx.doi.org/10.1155/2018/3867283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164208PMC
September 2018
3 Reads

Prevalence and Factors Associated with Anemia among Pregnant Women Attending Antenatal Clinic at St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.

Adv Hematol 2018 29;2018:3942301. Epub 2018 Aug 29.

Department of Medical Laboratory Sciences, College of Health Science, Addis Ababa University, Ethiopia.

Background: In pregnancy, anemia is an important factor associated with an increased risk of maternal, fetal, and neonatal mortality, poor pregnancy outcomes, and impaired cognitive development, particularly in developing countries like Ethiopia. This study aimed to assess prevalence and factors associated with anemia among pregnant women attending antenatal clinic at St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3942301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136568PMC
August 2018
11 Reads

Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis.

Adv Hematol 2017 6;2017:7878605. Epub 2017 Dec 6.

Department of Pediatrics, University Hospital of Ioannina, Ioannina, Greece.

Immune thrombocytopenia (ITP) in children has a varied course and according to duration is distinguished as newly diagnosed (<3 months), persistent (3-12), and chronic (>12) types. Several studies have evaluated the prognostic factors for the progression of the disease, but similar works have yet to be performed in Greece. We aimed to identify prognostic markers for the three forms of the disease in 57 Greek children during a 13-year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/7878605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736937PMC
December 2017
8 Reads

The rocky road to personalized medicine in acute myeloid leukaemia.

J Cell Mol Med 2018 Mar 12;22(3):1411-1427. Epub 2018 Jan 12.

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Acute myeloid leukaemia (AML) is a malignant disorder of the myeloid blood lineage characterized by impaired differentiation and increased proliferation of hematopoietic precursor cells. Recent technological advances have led to an improved understanding of AML biology but also uncovered the enormous cytogenetic and molecular heterogeneity of the disease. Despite this heterogeneity, AML is mostly managed by a 'one-size-fits-all' approach consisting of intensive, highly toxic induction and consolidation chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jcmm.13478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824388PMC
March 2018
2 Reads

Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy.

Adv Hematol 2017 8;2017:8690416. Epub 2017 Nov 8.

Stem Cell Transplant Program, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA.

In the era of precision medicine, the impact of personalized dosing of busulfan is not clear. We undertook a retrospective analysis of 78 patients with myeloid malignancies who received fludarabine and busulfan (FluBu4) with or without measuring Bu pharmacokinetics (Bu PK) and those who received busulfan with cyclophosphamide (BuCy). Fifty-five patients received FluBu4, of whom 21 had Bu PK measured, and 23 patients received BuCy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/8690416DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698787PMC
November 2017
13 Reads

Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.

Adv Hematol 2017 24;2017:6527306. Epub 2017 Oct 24.

Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. Immunogenic cancer testis antigens (CTAs), with their widespread expression in many tumours but highly restricted normal tissue distribution, represent attractive immunotherapeutic targets that may improve treatment options for DLBCL and other malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/6527306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674480PMC
October 2017
13 Reads

Efficacy and Safety of Manual Partial Red Cell Exchange in the Management of Severe Complications of Sickle Cell Disease in a Developing Country.

Adv Hematol 2017 11;2017:3518402. Epub 2017 May 11.

Hematology, Cheikh Anta Diop University, BP 5005, Dakar, Senegal.

Introduction: The realization of red cell exchange (RCE) in Africa faces the lack of blood, transfusion safety, and equipment. We evaluated its efficacy and safety in severe complications of sickle cell disease.

Patients And Method: Manual partial RCE was performed among sickle cell patients who had severe complications. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ah/2017/3518402/
Publisher Site
http://dx.doi.org/10.1155/2017/3518402DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443989PMC
May 2017
9 Reads

Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration.

Adv Exp Med Biol 2017 ;994:119-131

Division of Hematology & Oncology, University of California San Francisco, San Francisco, CA, 94115, USA.

The current standard methods for isolating circulating tumor cells (CTCs) from blood involve EPCAM-based immunomagnetic approaches. A major disadvantage of these strategies is that CTCs with low EPCAM expression will be missed. Isolation by size using filter membranes circumvents the reliance on this cell surface marker, and can facilitate the capture not only of EPCAM-negative CTCs but other rare cells as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-55947-6_6DOI Listing
October 2017
10 Reads

The Evolution of Prognostic Factors in Multiple Myeloma.

Adv Hematol 2017 21;2017:4812637. Epub 2017 Feb 21.

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the disease remains incurable. All efforts are currently focused on understanding the prognostic markers of the disease hoping to incorporate the new therapeutic modalities to convert the disease into curable one. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/4812637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339490PMC
February 2017
31 Reads

Autologous Graft-versus-Tumor Effect: Reality or Fiction?

Authors:
Luis F Porrata

Adv Hematol 2016 22;2016:5385972. Epub 2016 Aug 22.

Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

In contrast to allogeneic hematopoietic stem cell transplantation, the current dogma is not an evidence of graft-versus-tumor effect in autologous hematopoietic stem cell transplantation; thus, it is assumed that autologous hematopoietic stem cell transplantation only relies on the high-dose chemotherapy to improve clinical outcomes. However, recent studies argue in favor of the existence of an autologous graft-versus-tumor without the detrimental complications of graft-versus-host disease due to the nonspecific immune response from the infused donor alloreactive immune effector cells in allogeneic hematopoietic stem cell transplantation. Herein, this paper reviews the clinical evidence of an autologous graft-versus-tumor effect based on the autograft collected and infused host immune effector cells and host immunity recovery after autologous hematopoietic stem cell transplantation affecting clinical outcomes in cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/5385972DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011204PMC
September 2016
19 Reads

Clinical Scenarios for Discordant Anti-Xa.

Adv Hematol 2016 12;2016:4054806. Epub 2016 May 12.

Servicio de Gastrocirugía, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, 06720 México, DF, Mexico.

Anti-Xa test measures the activity of heparin against the activity of activated coagulation factor X; significant variability of anti-Xa levels in common clinical scenarios has been observed. Objective. To review the most common clinical settings in which anti-Xa results can be bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/4054806DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880685PMC
June 2016
74 Reads
1 Citation

Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance.

Adv Hematol 2016 30;2016:6471901. Epub 2016 Apr 30.

Bone Marrow Transplant Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

The induction of specific tolerance, in order to avoid the detrimental effects of lifelong systemic immunosuppressive therapy after organ transplantation, has been considered the "Holy Grail" of transplantation. Experimentally, tolerance has been achieved through clonal deletion, through costimulatory blockade, through the induction or infusion of regulatory T-cells, and through the establishment of hematopoietic chimerism following donor bone marrow transplantation. The focus of this review is how tolerance has been achieved following combined bone marrow and kidney transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/6471901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867066PMC
May 2016
13 Reads

Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt.

Adv Hematol 2016 17;2016:9032627. Epub 2016 Feb 17.

Department of Clinical Pathology, Faculty of Medicine, Sohag University, Sohag 82524, Egypt.

Background. Frequent blood transfusions in thalassemia major children expose them to the risk of transfusion-transmitted infections (TTIs). The aim of this study was to estimate the prevalence of hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and cytomegalovirus (CMV) in thalassemic children attending the Pediatrics Departments of both Sohag and Minia Universities of Upper Egypt, during the period from May 2014 to May 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/9032627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773519PMC
March 2016
21 Reads

Relative Susceptibilities of ABO Blood Groups to Plasmodium falciparum Malaria in Ghana.

Adv Hematol 2016 15;2016:5368793. Epub 2016 Feb 15.

Department of Biomedical and Forensic Sciences, University of Cape Coast, Cape Coast, Ghana.

The clinical outcome of falciparum malaria in endemic areas is influenced by erythrocyte polymorphisms including the ABO blood groups. Studies have reported association of ABO blood group to resistance, susceptibility, and severity of P. falciparum malaria infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/5368793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770114PMC
March 2016
15 Reads

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide.

Adv Hematol 2016 21;2016:9736564. Epub 2016 Jan 21.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA 30342, USA.

Relapse is the main cause of treatment failure after nonmyeloablative haploidentical transplant (haplo-HSCT). In an attempt to reduce relapse, we have developed a myeloablative (MA) haplo-HSCT approach utilizing posttransplant cyclophosphamide (PT/Cy) and peripheral blood stem cells as the stem cell source. We summarize the results of two consecutive clinical trials, using a busulfan-based (n = 20) and a TBI-based MA preparative regimen (n = 30), and analyze a larger cohort of 64 patients receiving MA haplo-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/9736564DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745340PMC
February 2016
13 Reads

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.

Adv Hematol 2015 30;2015:612567. Epub 2015 Dec 30.

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.

BCR-ABL-mediated leukemias, either Chronic Myeloid Leukemia (CML) or Philadelphia positive Acute Lymphoblastic Leukemia (ALL), are the paradigm of targeted molecular therapy of cancer due to the impressive clinical responses obtained with BCR-ABL specific tyrosine kinase inhibitors (TKIs). However, BCR-ABL TKIs do not allow completely eradicating both CML and ALL. Furthermore, ALL therapy is associated with much worse responses to TKIs than those observed in CML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/612567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710905PMC
February 2016
13 Reads

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation.

Adv Hematol 2015 2;2015:431923. Epub 2015 Dec 2.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.

The implementation of high-dose posttransplantation cyclophosphamide (PTCy) has made HLA-haploidentical (haplo) blood or marrow transplantation (BMT) a cost effective and safe alternative donor transplantation technique, resulting in its increasing utilization over the last decade. We review the available retrospective comparisons of haplo BMT with PTCy and HLA-matched BMT in adults with hematologic malignancies. The examined studies demonstrate no difference between haplo BMT with PTCy and HLA-matched BMT with regard to acute graft-versus-host disease (aGVHD), nonrelapse mortality, and overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/431923DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680052PMC
December 2015
16 Reads

Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Adv Hematol 2015 9;2015:848473. Epub 2015 Nov 9.

Novartis Pharma AG, 4056 Basel, Switzerland.

Few trial-based assessments of ruxolitinib in patients with lower-risk myelofibrosis (MF) have been conducted, and no studies have made such assessments in a real-world population. We assessed changes in spleen size and constitutional symptoms during ruxolitinib treatment using a retrospective, observational review of anonymized US medical record data of patients diagnosed with IPSS low-risk (n = 25) or intermediate-1-risk (n = 83) MF. The majority of patients were male (low risk, 60%; intermediate-1 risk, 69%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/848473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655278PMC
December 2015
12 Reads

Profiling β Thalassemia Mutations in Consanguinity and Nonconsanguinity for Prenatal Screening and Awareness Programme.

Adv Hematol 2015 21;2015:625721. Epub 2015 Oct 21.

Department of Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014, India.

Mutation spectrum varies significantly in different parts and different ethnic groups of India. Social factors such as preference to marry within the community and among 1st degree relatives (consanguinity) play an important role in impeding the gene pool of the disease within the community and so in society by and large. The present paper discusses the role of consanguinity in profiling of beta thalassemia mutation, and thus the approach for prenatal screening and prevention based awareness programme. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/625721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631845PMC
November 2015
23 Reads

The Iron Status of Sickle Cell Anaemia Patients in Ilorin, North Central Nigeria.

Adv Hematol 2015 15;2015:386451. Epub 2015 Oct 15.

Department of Family Medicine, Kwara State Specialist Hospital, Sobi, 240001 Ilorin, Nigeria.

Objectives. Sickle cell anaemia (SCA) is one of the commonest genetic disorders in the world. It is characterized by anaemia, periodic attacks of thrombotic pain, and chronic systemic organ damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/386451DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624881PMC
November 2015
15 Reads

Predictors of Outcome and Severity in Adult Filipino Patients with Febrile Neutropenia.

Adv Hematol 2015 3;2015:920838. Epub 2015 Sep 3.

Department of Medicine, Philippine General Hospital, Taft Avenue, Ermita, 1000 Manila, Philippines.

Aim. The study aimed to describe the profile of Filipino febrile neutropenia patients and to determine parameters associated with severe outcomes. Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/920838DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573217PMC
September 2015
10 Reads

Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions.

Adv Hematol 2015 18;2015:315289. Epub 2015 Aug 18.

Department of Oncology, Prince Sultan Military Medical City, Saudi Arabia.

Plasmablastic lymphoma (PBL) is an aggressive subtype of non-Hodgkin's lymphoma (NHL), which frequently arises in the oral cavity of human immunodeficiency virus (HIV) infected patients. PBL shows diffuse proliferation of large neoplastic cells resembling B-immunoblasts/plasmablasts, or with plasmacytic features and an immunophenotype of plasma cells. PBL remains a diagnostic challenge due to its peculiar morphology and an immunohistochemical profile similar to plasma cell myeloma (PCM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/315289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555447PMC
September 2015
28 Reads

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies.

Adv Hematol 2015 19;2015:431268. Epub 2015 Aug 19.

Bayer HealthCare, 100 Bayer Boulevard, P.O. Box 915, Whippany, NJ 08981-0915, USA.

Objectives. Prophylaxis regimens for severe hemophilia A allowing more flexible dosing while maintaining efficacy may improve adherence and decrease the cost of prophylaxis. Here, we compared the clinical effectiveness of once- or twice-weekly versus ≥3-times-weekly prophylaxis with sucrose-formulated recombinant factor VIII (rFVIII-FS) in a "real-world" practice setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/431268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556870PMC
September 2015
19 Reads

Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence.

Adv Hematol 2015 16;2015:920361. Epub 2015 Aug 16.

Section of Thrombosis & Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Vitamin K antagonists (VKA) and heparins have been utilized for the prevention and treatment of thromboembolism (arterial and venous) for decades. Targeting and inhibiting specific coagulation factors have led to new discoveries in the pharmacotherapy of thromboembolism management. These targeted anticoagulants are known as direct oral anticoagulants (DOACs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/920361DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553175PMC
September 2015
21 Reads
3 Citations

The evolution of guidelines for the validation of flow cytometric methods.

Int J Lab Hematol 2015 May;37 Suppl 1:3-10

Hematology, Covance, Indianapolis, IN, USA.

The recent advances in the field of flow cytometry have resulted in instrumentation with increased capacity which is actually more user-friendly. Thus, the technology has become more valuable to research scientists, the pharmaceutical industry and clinical laboratories. The use of flow cytometry in regulated labs has been hampered by the challenges associated method validation and the lack of official guidance documents on the topic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijlh.12344DOI Listing
May 2015
9 Reads

Advances in Targeted Therapy for Breast Cancer.

Fed Pract 2015 May;32(Suppl 4):46S-49S

is a fellow in hematology/oncology and is an associate professor of medicine, both at The George Washington University in Washington, DC. Dr. Aggarwal is also an associate professor of medicine at Georgetown University and a hematologist/oncologist at the Washington DC VAMC, both in Washington, DC. She is also president elect of Association of VA Hematology and Oncology..

Recent clinical trials have provided additional first-line therapeutic treatment options that improve overall survival and progression-free survival in women with breast cancer. Read More

View Article

Download full-text PDF

Source

Impaired fibrinolysis in angiographically documented coronary artery disease.

Adv Hematol 2015 23;2015:214680. Epub 2015 Feb 23.

Faculty of Pharmacy, Federal University of Minas Gerais, Avenida Antonio Carlos 6627, 31270-901 Belo Horizonte, MG, Brazil.

Impaired fibrinolysis may predispose to coronary artery disease (CAD). Hypofibrinolysis due to high levels of plasminogen activator inhibitor-1 (PAI-1) has been reported in CAD. A novel regulator of fibrinolytic activity, thrombin activatable fibrinolysis inhibitor (TAFI), has attracted attention in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/214680DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355601PMC
March 2015
12 Reads

Persistent Polyclonal B Cell Lymphocytosis B Cells Can Be Activated through CD40-CD154 Interaction.

Adv Hematol 2014 14;2014:854124. Epub 2014 Dec 14.

Centre Universitaire d'Hématologie et d'Oncologie de Québec, CHU de Québec, Hôpital de l'Enfant-Jésus, 1401 18ième rue, Québec, QC, Canada G1J 1Z4.

Persistent polyclonal B cell lymphocytosis (PPBL) is a rare disorder, diagnosed primarily in adult female smokers and characterized by an expansion of CD19(+)CD27(+)IgM(+) memory B cells, by the presence of binucleated lymphocytes, and by a moderate elevation of serum IgM. The clinical course is usually benign, but it is not known whether or not PPBL might be part of a process leading to the emergence of a malignant proliferative disorder. In this study we sought to investigate the functional response of B cells from patients with PPBL by use of an optimal memory B cell culture model based on the CD40-CD154 interaction. Read More

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/ah/2014/854124/
Publisher Site
http://dx.doi.org/10.1155/2014/854124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279877PMC
January 2015
12 Reads

Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.

Adv Hematol 2014 16;2014:932039. Epub 2014 Nov 16.

Department of Medical Laboratory Science (Haematology and Blood Group Serology Unit), University of Calabar, PMB 1115, Calabar, Cross River State, Nigeria.

Introduction. Several biomedical findings have established the effects of hypertension on haemostasis and roles of blood coagulation products in the clinical course of hypertension. Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/932039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248403PMC
December 2014
74 Reads

Prevalence and Specificity of RBC Alloantibodies in Indian Patients Attending a Tertiary Care Hospital.

Adv Hematol 2014 16;2014:749218. Epub 2014 Oct 16.

Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi 110029, India.

Background. Red blood cell (RBC) alloimmunization results from genetic disparity of RBC antigens between donor and recipients. Data about alloimmunization rate in general patient population is scarce especially from resource limited countries. Read More

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/ah/2014/749218/
Publisher Site
http://dx.doi.org/10.1155/2014/749218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216689PMC
November 2014
5 Reads

Ethical and clinical aspects of intensive care unit admission in patients with hematological malignancies: guidelines of the ethics commission of the French society of hematology.

Adv Hematol 2014 1;2014:704318. Epub 2014 Oct 1.

Ethics Commission of the French Society of Hematology, France ; Hematology Department of the University of Limoges, 87042 Limoges, France.

Admission of patients with hematological malignancies to intensive care unit (ICU) raises recurrent ethical issues for both hematological and intensivist teams. The decision of transfer to ICU has major consequences for end of life care for patients and their relatives. It also impacts organizational human and economic aspects for the ICU and global health policy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/704318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199072PMC
October 2014
17 Reads

Variation of red blood cell distribution width and mean platelet volume after moderate endurance exercise.

Adv Hematol 2014 13;2014:192173. Epub 2014 Aug 13.

Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Via delle Menegone, 37100 Verona, Italy.

Although physical exercise strongly influences several laboratory parameters, data about the hematological changes after medium distance running are scarce. We studied 31 middle-trained athletes (mean training regimen 217 ± 32 min/week) who performed a 21.1 km, half-marathon run. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/192173DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147199PMC
September 2014
11 Reads

Hypertransfusion therapy in sickle cell disease in Nigeria.

Adv Hematol 2014 7;2014:923593. Epub 2014 Aug 7.

Department of Haematology and Blood Transfusion, University of Benin Teaching Hospital, PMB 1111, Benin City, Edo State, Nigeria.

Introduction. Hypertransfusion refers to chronic blood transfusion therapy aimed at ameliorating disease complications in various haemopathies particularly the haemoglobinopathies. In sickle cell disease, hypertransfusion is aimed at maintaining patient's haemoglobin level at 10 to 11 g/dL using haemoglobin AA blood and its resultant dilutional effect on sickle haemoglobin is sustained by intermittent long-term transfusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/923593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142279PMC
September 2014
8 Reads
3 Citations

Absence of Association between CCR5 rs333 Polymorphism and Childhood Acute Lymphoblastic Leukemia.

Adv Hematol 2014 13;2014:924030. Epub 2014 Apr 13.

Laboratory of Study and Application of DNA Polymorphisms, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Rodovia Celso Garcia Cid, (PR 445), Km 380, 86051-970 Londrina, PR, Brazil.

Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage. Ordinarily, these cells express CCR5 chemokine receptor, which directs the immune response to a cellular pattern and is involved in cancer pathobiology. The genetic rs333 polymorphism of CCR5 (Δ32), results in a diminished receptor expression, thus leading to impaired cell trafficking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/924030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009163PMC
May 2014
4 Reads

The genetic architecture of multiple myeloma.

Adv Hematol 2014 3;2014:864058. Epub 2014 Apr 3.

Brighton and Sussex Medical School, Sussex University, Falmer, Brighton BN1 9PS, UK.

Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical features that include hypercalcaemia, renal dysfunction, anaemia, and bone disease (frequently referred to by the acronym CRAB) which represent evidence of end organ failure. Recent evidence has revealed myeloma to be a highly heterogeneous disease composed of multiple molecularly-defined subtypes each with varying clinicopathological features and disease outcomes. The major division within myeloma is between hyperdiploid and nonhyperdiploid subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/864058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996928PMC
May 2014
4 Reads

The epigenetic landscape of acute myeloid leukemia.

Adv Hematol 2014 23;2014:103175. Epub 2014 Mar 23.

Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton BN1 9PS, UK.

Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Certain cytogenetic and molecular genetic mutations are recognized to have an impact on prognosis, leading to their inclusion in some prognostic stratification systems. Recently, the advent of high-throughput whole genome or exome sequencing has led to the identification of several novel recurrent mutations in AML, a number of which have been found to involve genes concerned with epigenetic regulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/103175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980839PMC
May 2014
5 Reads

Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma.

Adv Hematol 2014 2;2014:512508. Epub 2014 Mar 2.

Hematology Department of the University of Amiens, Amiens, France ; University Hospital of Amiens, Department of Clinical Haematology, Avenue Laennec, 80054 Amiens, France.

Background. Primary bone lymphoma (PBL) is a rare entity that has only been reviewed in one prospective and small retrospective studies, from which it is difficult to establish treatment guidelines. We prospectively evaluated high-dose or conventional anthracycline-cyclophosphamide dose and radiotherapy for PBL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/512508DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958647PMC
April 2014
1 Read

Influence of the Clinical Status on Stress Reticulocytes, CD 36 and CD 49d of SSFA 2 Homozygous Sickle Cell Patients Followed in Abidjan.

Adv Hematol 2014 27;2014:273860. Epub 2014 Feb 27.

, , , , AIDS Biological Unit, Central Laboratory, Teaching Hospital of Yopougon, BP 632 Abidjan 21, Cote D'Ivoire.

Background and Objectives. Interactions between sickle cells involving CD 49d, CD36, and the vascular endothelium may initiate vasoocclusion leading to acute painful episodes and multiple organ failure. Materials and Methods. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/273860DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955669PMC
April 2014
1 Read

Procoagulant phospholipids and tissue factor activity in cerebrospinal fluid from patients with intracerebral haemorrhage.

Adv Hematol 2014 17;2014:576750. Epub 2014 Feb 17.

Clinical Biology Department & EA 4531, Hospital Foch, 40 rue Worth, 92151 Suresnes Cedex, France.

Brain contains large amounts of tissue factor, the major initiator of the coagulation cascade. Neuronal apoptosis after intracerebral haemorrhage (ICH) leads to the shedding of procoagulant phospholipids (PPLs). The aim of this study was to investigate the generation of PPL, tissue factor activity (TFa), and D-Dimer (D-Di) in the cerebrospinal fluid (CSF) at the acute phase of ICH in comparison with other brain diseases and to examine the relationship between these factors and the outcome of ICH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/576750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947823PMC
April 2014
1 Read

Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.

Adv Hematol 2014 20;2014:141360. Epub 2014 Feb 20.

Department of Adult Clinical Hematology and Stem Cell Therapy, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia (AML). AML patients with FLT3 internal tandem duplication (ITD) mutations have poor cure rates the prognostic significance of point mutations; tyrosine kinase domain (TKD) is still unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/141360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950551PMC
April 2014
11 Reads

The observation report of red blood cell morphology in Thailand teenager by using data mining technique.

Adv Hematol 2014 13;2014:493706. Epub 2014 Feb 13.

Division of Clinical Microscopy, Faculty of Medical Technology, Huachiew Chalermprakiet University, Samut Prakan 10540, Thailand.

It is undeniable that laboratory information is important in healthcare in many ways such as management, planning, and quality improvement. Laboratory diagnosis and laboratory results from each patient are organized from every treatment. These data are useful for retrospective study exploring a relationship between laboratory results and diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2014/493706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943190PMC
March 2014
25 Reads

Clinically Significant Minor Blood Group Antigens amongst North Indian Donor Population.

Adv Hematol 2013 9;2013:215454. Epub 2013 Dec 9.

Department of Transfusion Medicine, Block D, Level II, Government Medical College & Hospital, Chandigarh 160030, India.

Background. Racial differences in blood group antigen distribution are common and may result in striking and interesting findings. These differences in blood group antigen distribution are important due to their influence on the clinical practice of transfusion medicine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/215454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893736PMC
February 2014
2 Reads

Characteristics and Results of the Treatment of Multiple Myeloma in the Subject under the Age of 65 at the University Hospital of Yopougon in Abidjan, Côte d'Ivoire.

Adv Hematol 2013 26;2013:583051. Epub 2013 Dec 26.

Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d'Ivoire.

We retrospectively studied 30 cases of multiple myeloma in patients under the age of 65, diagnosed from 1991 to 2005 in the clinical hematology department of the University Hospital of Yopougon that is a hospital incidence of 2.9 cases/year. The age of patients ranged from 34 to 64 years, with a mean age of 49 years and a sex ratio of 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/583051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886227PMC
January 2014
14 Reads

Sonoclot signature analysis in patients with liver disease and its correlation with conventional coagulation studies.

Adv Hematol 2013 11;2013:237351. Epub 2013 Dec 11.

Department of Hepatology, Institute of Liver and Biliary Sciences, D-1, Vasant Kunj, New Delhi 110070, India.

Introduction. Liver disease patients have complex hemostatic defects leading to a delicate, unstable balance between bleeding and thrombosis. Conventional tests such as PT and APTT are unable to depict these defects completely. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/237351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874319PMC
January 2014
36 Reads
3 Citations

Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience.

Adv Hematol 2013 28;2013:151506. Epub 2013 Oct 28.

Shaare Zedek Medical Center, Affiliated to the Hadassah-Hebrew University School of Medicine, Ein Karem 91031, Israel.

Gaucher disease, a lysosomal storage disorder, is a multisystem disorder with variable and unpredictable onset and severity. Disease-specific enzyme replacement therapy (ERT) has been shown to reverse or ameliorate disease-specific hepatosplenomegaly and anemia and thrombocytopenia. ERT also impacts bone manifestations, including bone crises, bone pain, and appearance of new osteonecrosis, and improves bone mineral density to varying degrees. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2013/151506DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830843PMC
November 2013
4 Reads